Skip to main content
Erschienen in:

01.08.2009 | Weiterbildung • Zertifizierte Fortbildung

Behandlung der Patientinnen mit HER2- (ErbB2-) positivem Mammakarzinom

Ein Paradebeispiel für die Übertragung molekularer Erkenntnisse in die Klinik

verfasst von: Prof. Dr. M. Untch, C. Jackisch

Erschienen in: Die Onkologie | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Identifikation von prognostischen und prädiktiven Faktoren hat für die Effektivität der Therapie bei Brustkrebspatientinnen eine sehr große Bedeutung. Der epidermale Wachstumsfaktorrezeptor 2 (HER2, ErbB2) wird bei etwa 20% aller invasiven Mammakarzinome überexprimiert. Dies ist mit einer schlechten Prognose mit kürzerem rezidivfreiem Überleben und Gesamtüberleben assoziiert. Der gegen HER2 gerichtete Antikörper Trastuzumab konnte über alle Therapielinien hinweg einen meist signifikanten Benefit bei HER2-positiven Patientinnen im Vergleich zu herkömmlichen Therapien demonstrieren. Dennoch gibt es eine substanzielle Anzahl von Patientinnen, die nicht auf den Antikörper ansprechen oder rezidivieren. Für diese Patientinnen steht mit dem Tyrosinkinasehemmer Lapatinib, der einen unterschiedlichen Angriffspunkt an der HER2-vermittelten Signalkaskade aufweist, eine weitere Option zur Verfügung. Mögliche synergistische Effekte werden derzeit in großen randomisierten Studien geprüft, denn die bestmögliche Therapiestrategie für Patientinnen mit HER2-positiven Mammakarzinomen ist nach wie vor nicht eindeutig definiert.
Literatur
1.
Zurück zum Zitat Arnould L, Gelly M, Penault-Llorca F et al (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259–267PubMedCrossRef Arnould L, Gelly M, Penault-Llorca F et al (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259–267PubMedCrossRef
2.
Zurück zum Zitat Barnholtz-Sloan JS, Sloan AE, Davis FG et al (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865–2872PubMedCrossRef Barnholtz-Sloan JS, Sloan AE, Davis FG et al (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865–2872PubMedCrossRef
3.
Zurück zum Zitat Bell R Bell R, Feng-Yi F, Barrioset et al (2007) Trastuzumab retreatment in patients who relapse following adjuvant trastuzumab therapy: preliminary efficacy from the RHEA trial. Breast Cancer Symposium. San Francisco, Abstr 245 Bell R Bell R, Feng-Yi F, Barrioset et al (2007) Trastuzumab retreatment in patients who relapse following adjuvant trastuzumab therapy: preliminary efficacy from the RHEA trial. Breast Cancer Symposium. San Francisco, Abstr 245
4.
Zurück zum Zitat Bendell J, Domchek SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977PubMedCrossRef Bendell J, Domchek SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977PubMedCrossRef
5.
Zurück zum Zitat Berns K, Horlings HM, Hennessy BT et al (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395–402PubMedCrossRef Berns K, Horlings HM, Hennessy BT et al (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395–402PubMedCrossRef
6.
Zurück zum Zitat Burris HA (2004) Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9 (Suppl 3):10–15PubMedCrossRef Burris HA (2004) Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9 (Suppl 3):10–15PubMedCrossRef
7.
Zurück zum Zitat Burris HA, Storniolo AM, Overmoyer EA et al (2004) A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. Breast Can Res Treat. 2004;88:S126. Abstract 3043 Burris HA, Storniolo AM, Overmoyer EA et al (2004) A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. Breast Can Res Treat. 2004;88:S126. Abstract 3043
8.
Zurück zum Zitat Carlson RW, Anderson BO, Burstein HJ et al; National Comprehensive Cancer Network (2005) Breast cancer. J Natl Compr Canc Netw 3:238–289PubMed Carlson RW, Anderson BO, Burstein HJ et al; National Comprehensive Cancer Network (2005) Breast cancer. J Natl Compr Canc Netw 3:238–289PubMed
9.
Zurück zum Zitat Carlson RW, Moench SJ, Hammond ME et al; NCCN HER2 Testing in Breast Cancer Task Force (2006) HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 4 (Suppl 3):S1–S22 Carlson RW, Moench SJ, Hammond ME et al; NCCN HER2 Testing in Breast Cancer Task Force (2006) HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 4 (Suppl 3):S1–S22
10.
Zurück zum Zitat Christianson TA, Doherty JK, Lin YJ et al (1998) NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 58:5123–5129PubMed Christianson TA, Doherty JK, Lin YJ et al (1998) NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 58:5123–5129PubMed
11.
Zurück zum Zitat Clayton AJ, Danson S, Jolly S et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639–643PubMed Clayton AJ, Danson S, Jolly S et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639–643PubMed
12.
Zurück zum Zitat Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, Deutsche Krebsgesellschaft (2008) Interdisziplinäre S3-Leilinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms der deutschen Gesellschaft für Gynäkologie und Geburtshilfe und der deutschen Krebsgesellschaft, Update I/2008 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, Deutsche Krebsgesellschaft (2008) Interdisziplinäre S3-Leilinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms der deutschen Gesellschaft für Gynäkologie und Geburtshilfe und der deutschen Krebsgesellschaft, Update I/2008
13.
Zurück zum Zitat Di Leo A, Gomez H, Aziz Z et al (2007) Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 (18 Suppl): 1011 Di Leo A, Gomez H, Aziz Z et al (2007) Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 (18 Suppl): 1011
14.
Zurück zum Zitat Fujita T, Doihara H, Kawasaki K et al (2006) PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 94:247–252PubMedCrossRef Fujita T, Doihara H, Kawasaki K et al (2006) PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 94:247–252PubMedCrossRef
15.
Zurück zum Zitat Gelon KA, Mackey J, Verma S et al (2004) Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 5:52–58CrossRef Gelon KA, Mackey J, Verma S et al (2004) Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 5:52–58CrossRef
16.
Zurück zum Zitat Gennari R, Menard S, Fagnoni F et al (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:5650–5655PubMedCrossRef Gennari R, Menard S, Fagnoni F et al (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:5650–5655PubMedCrossRef
17.
Zurück zum Zitat Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743PubMedCrossRef Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743PubMedCrossRef
18.
Zurück zum Zitat Geyer CE, Martin A, Newstat B et al (2007) Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 (18 Suppl):1035 Geyer CE, Martin A, Newstat B et al (2007) Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 (18 Suppl):1035
19.
Zurück zum Zitat Gianni L, Eiermann W, Semiglazov V, et al et al (2009) Neoadjuvant Trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial Cancer Res 69 (Suppl 2): Abstr 31 Gianni L, Eiermann W, Semiglazov V, et al et al (2009) Neoadjuvant Trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial Cancer Res 69 (Suppl 2): Abstr 31
20.
Zurück zum Zitat Gianni L, Goldhirsch A, Gelber RD et al (2009) Update of the HERA trial and the role of 1 year trastuzumab as adjuvant therapy for breast cancer. Breast 18 (Suppl 1): Abstr S25 Gianni L, Goldhirsch A, Gelber RD et al (2009) Update of the HERA trial and the role of 1 year trastuzumab as adjuvant therapy for breast cancer. Breast 18 (Suppl 1): Abstr S25
21.
Zurück zum Zitat Guarneri V, Frassoldati A, Bruzzi P et al (2008) Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer 8:453–456PubMedCrossRef Guarneri V, Frassoldati A, Bruzzi P et al (2008) Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer 8:453–456PubMedCrossRef
22.
Zurück zum Zitat Guix M M, Aura CM, Jimenez J et al (2008) Lapatinib is active in patients with HER2-amplified breast tumors expressing p95HER2. San Antonio Breast Cancer Symposium, Abstr 708 Guix M M, Aura CM, Jimenez J et al (2008) Lapatinib is active in patients with HER2-amplified breast tumors expressing p95HER2. San Antonio Breast Cancer Symposium, Abstr 708
23.
Zurück zum Zitat Hudis CA (2007) Trastuzumab – mechanism of action and use in clinical practice. N Engl J Med 357:39–51PubMedCrossRef Hudis CA (2007) Trastuzumab – mechanism of action and use in clinical practice. N Engl J Med 357:39–51PubMedCrossRef
24.
Zurück zum Zitat Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354PubMedCrossRef Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354PubMedCrossRef
25.
Zurück zum Zitat Izumi Y, Xu L, di Tomaso E et al (2002) Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416:279–280PubMedCrossRef Izumi Y, Xu L, di Tomaso E et al (2002) Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416:279–280PubMedCrossRef
26.
27.
Zurück zum Zitat Joensuu H et al (2009) Update of the FINHER trial based on 5 years of follow-up. Breast 18 (Suppl 1): Abstr S24CrossRef Joensuu H et al (2009) Update of the FINHER trial based on 5 years of follow-up. Breast 18 (Suppl 1): Abstr S24CrossRef
28.
Zurück zum Zitat Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al; FinHer Study Investigators (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809–820PubMedCrossRef Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al; FinHer Study Investigators (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809–820PubMedCrossRef
29.
Zurück zum Zitat Johnston S, Pegram M, Press M et al (2008) Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. San Antonio Breast Cancer Symposium, Abstr 46 Johnston S, Pegram M, Press M et al (2008) Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. San Antonio Breast Cancer Symposium, Abstr 46
30.
Zurück zum Zitat Kallioniemi OP, Holli K, Visakorpi T et al (1991) Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650–655PubMedCrossRef Kallioniemi OP, Holli K, Visakorpi T et al (1991) Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650–655PubMedCrossRef
31.
Zurück zum Zitat Krop IE, Winer EP (2009) Ten years of HER2-directed therapy: still questions after all these years. Breast Cancer Res Treat 113:207–209PubMedCrossRef Krop IE, Winer EP (2009) Ten years of HER2-directed therapy: still questions after all these years. Breast Cancer Res Treat 113:207–209PubMedCrossRef
32.
Zurück zum Zitat Lin N, Dieras V, Paul D al (2007) EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). ASCO Annual Meeting Proceedings Part I. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 (18 Suppl):1012 Lin N, Dieras V, Paul D al (2007) EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). ASCO Annual Meeting Proceedings Part I. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 (18 Suppl):1012
33.
Zurück zum Zitat Longva KE, Pedersen NM, Haslekås C et al (2005) Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 116:359–367PubMedCrossRef Longva KE, Pedersen NM, Haslekås C et al (2005) Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 116:359–367PubMedCrossRef
34.
Zurück zum Zitat Migliaccio I, Gutierrez MC, Wu MF et al (2008) PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC). San Antonio Breast Cancer Symposium, Abstr 34 Migliaccio I, Gutierrez MC, Wu MF et al (2008) PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC). San Antonio Breast Cancer Symposium, Abstr 34
35.
Zurück zum Zitat Minckwitz G von, du Bois A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 27:1999–2006CrossRef Minckwitz G von, du Bois A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 27:1999–2006CrossRef
36.
Zurück zum Zitat Minckwitz G von, Kaufmann M, Kümmel S et al (2008) Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy. San Antonio Breast Cancer Symposium, Oral Session #79 Minckwitz G von, Kaufmann M, Kümmel S et al (2008) Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy. San Antonio Breast Cancer Symposium, Oral Session #79
37.
Zurück zum Zitat Molina MA, Codony-Servat J, Albanell J et al (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61:4744–4749PubMed Molina MA, Codony-Servat J, Albanell J et al (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61:4744–4749PubMed
38.
Zurück zum Zitat Moss S, Thomas I, Evans A et al; Trial Management Group (2005) Randomised controlled trial of mammographic screening in women from age 40: results of screening in the first 10 years. Br J Cancer 92:949–954PubMedCrossRef Moss S, Thomas I, Evans A et al; Trial Management Group (2005) Randomised controlled trial of mammographic screening in women from age 40: results of screening in the first 10 years. Br J Cancer 92:949–954PubMedCrossRef
39.
Zurück zum Zitat Moy B, Maltzman D, Rappold E et al (2009) TEACH: Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with HER2-positive breast cancer. Breast 18 (Suppl 1): 58, Abstr 154 Moy B, Maltzman D, Rappold E et al (2009) TEACH: Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with HER2-positive breast cancer. Breast 18 (Suppl 1): 58, Abstr 154
40.
Zurück zum Zitat Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117–127PubMedCrossRef Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117–127PubMedCrossRef
41.
Zurück zum Zitat Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117–127PubMedCrossRef Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117–127PubMedCrossRef
42.
Zurück zum Zitat Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232:123–138PubMedCrossRef Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232:123–138PubMedCrossRef
43.
Zurück zum Zitat National Cancer Institute (2008) Trastuzumab for 6 months or 1 year in treating women with nonmetastatic breast cancer that can be removed by surgery. http://clinicaltrials.gov/show/NCT00381901 National Cancer Institute (2008) Trastuzumab for 6 months or 1 year in treating women with nonmetastatic breast cancer that can be removed by surgery. http://​clinicaltrials.​gov/​show/​NCT00381901
44.
Zurück zum Zitat Nelson MH, Dolder CR (2006) Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40:261–269PubMedCrossRef Nelson MH, Dolder CR (2006) Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40:261–269PubMedCrossRef
45.
Zurück zum Zitat Perez E, Romond EH, Suman VJ et al (2007) Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 (Suppl):512CrossRef Perez E, Romond EH, Suman VJ et al (2007) Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 (Suppl):512CrossRef
46.
Zurück zum Zitat Rakkhit R, Broglio K, Peintinger F et al (2008) Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. San Antonio Breast Cancer Symposium, Abstr 701 Rakkhit R, Broglio K, Peintinger F et al (2008) Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. San Antonio Breast Cancer Symposium, Abstr 701
47.
Zurück zum Zitat Rugo HS, Kaufman P, Tan-Chiu E et al (2008) Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER. San Antonio Breast Cancer Symposium, Abstr 3142 Rugo HS, Kaufman P, Tan-Chiu E et al (2008) Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER. San Antonio Breast Cancer Symposium, Abstr 3142
48.
Zurück zum Zitat Rusnak DW, Affleck K, Cockerill SG et al (2001) The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 61:7196–7203PubMed Rusnak DW, Affleck K, Cockerill SG et al (2001) The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 61:7196–7203PubMed
49.
Zurück zum Zitat Saal LH, Holm K, Maurer M et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554–2559PubMedCrossRef Saal LH, Holm K, Maurer M et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554–2559PubMedCrossRef
50.
Zurück zum Zitat Saez R, Molina MA, Ramsey EE et al (2006) p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 12:424–431PubMedCrossRef Saez R, Molina MA, Ramsey EE et al (2006) p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 12:424–431PubMedCrossRef
51.
Zurück zum Zitat Scaltriti M, Rojo F, Ocaña A et al (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628–638PubMedCrossRef Scaltriti M, Rojo F, Ocaña A et al (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628–638PubMedCrossRef
52.
Zurück zum Zitat Slamon DJ et al (2006) 29th Annual San Antonio Breast Cancer Symposium –December 14–17, 2006. Breast Cancer Res Treat 94 (Suppl 1) Slamon DJ et al (2006) 29th Annual San Antonio Breast Cancer Symposium –December 14–17, 2006. Breast Cancer Res Treat 94 (Suppl 1)
53.
Zurück zum Zitat Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedCrossRef Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedCrossRef
54.
Zurück zum Zitat Slamon DJ, Eiermann W, Robert N et al (2006) BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium, Abstr 52 Slamon DJ, Eiermann W, Robert N et al (2006) BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium, Abstr 52
55.
Zurück zum Zitat Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–7012PubMedCrossRef Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–7012PubMedCrossRef
56.
Zurück zum Zitat Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRef Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRef
57.
Zurück zum Zitat Smith I, Procter M, Gelber RD et al; HERA study team (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29–36PubMedCrossRef Smith I, Procter M, Gelber RD et al; HERA study team (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29–36PubMedCrossRef
58.
Zurück zum Zitat Stemmler HJ, Kahlert S, Siekiera W (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15:219–225PubMedCrossRef Stemmler HJ, Kahlert S, Siekiera W (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15:219–225PubMedCrossRef
59.
Zurück zum Zitat Storniolo AM, Pegram MD, Overmoyer B (2008) Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 26:3317–3323PubMedCrossRef Storniolo AM, Pegram MD, Overmoyer B (2008) Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 26:3317–3323PubMedCrossRef
60.
Zurück zum Zitat Untch M, Gelber RD, Jackisch C et al; HERA Study Team (2008) Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 18:1090–1096CrossRef Untch M, Gelber RD, Jackisch C et al; HERA Study Team (2008) Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 18:1090–1096CrossRef
61.
Zurück zum Zitat Untch M, Rezai M, Loibl S et al (2008) Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study „GeparQuattro“. Eur J Cancer (Suppl 6): 47 Untch M, Rezai M, Loibl S et al (2008) Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study „GeparQuattro“. Eur J Cancer (Suppl 6): 47
62.
Zurück zum Zitat Untch M, Stoeckl D, Konecny G et al (2005) A multicenter phase II study of preoperative epirubicin, cyclophosphamide (EC) followed by paclitaxel (P) plus trastuzumab (T) in Her2 positive primary breast cancer. Breast Cancer Res Treat 94 (Suppl 1): Abstr 1064 Untch M, Stoeckl D, Konecny G et al (2005) A multicenter phase II study of preoperative epirubicin, cyclophosphamide (EC) followed by paclitaxel (P) plus trastuzumab (T) in Her2 positive primary breast cancer. Breast Cancer Res Treat 94 (Suppl 1): Abstr 1064
63.
Zurück zum Zitat Viani GA, Afonso SL, Stefano EJ et al (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153PubMedCrossRef Viani GA, Afonso SL, Stefano EJ et al (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153PubMedCrossRef
64.
Zurück zum Zitat Vogel C, Cobleigh MA, Tripathy D et al (2001) First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report. Eur J Cancer 37 (Suppl 1):25–29PubMedCrossRef Vogel C, Cobleigh MA, Tripathy D et al (2001) First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report. Eur J Cancer 37 (Suppl 1):25–29PubMedCrossRef
65.
Zurück zum Zitat Vukelja S, Rugo H, Vogel C et al (2008) A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer. San Antonio Breast Cancer Symposium, Abstr 33 Vukelja S, Rugo H, Vogel C et al (2008) A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer. San Antonio Breast Cancer Symposium, Abstr 33
66.
Zurück zum Zitat Wolff AC, Hammond ME, Schwartz JN et al; American Society of Clinical Oncology; College of American Pathologists (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145PubMedCrossRef Wolff AC, Hammond ME, Schwartz JN et al; American Society of Clinical Oncology; College of American Pathologists (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145PubMedCrossRef
67.
Zurück zum Zitat Xia W, Liu LH, Ho P, Spector NL (2004) Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23:646–653PubMedCrossRef Xia W, Liu LH, Ho P, Spector NL (2004) Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23:646–653PubMedCrossRef
68.
Zurück zum Zitat Yau T, Swanton C, Chua S et al (2006) Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45:196–201PubMed Yau T, Swanton C, Chua S et al (2006) Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45:196–201PubMed
69.
Zurück zum Zitat Cameron D et al. (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533–543PubMedCrossRef Cameron D et al. (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533–543PubMedCrossRef
Metadaten
Titel
Behandlung der Patientinnen mit HER2- (ErbB2-) positivem Mammakarzinom
Ein Paradebeispiel für die Übertragung molekularer Erkenntnisse in die Klinik
verfasst von
Prof. Dr. M. Untch
C. Jackisch
Publikationsdatum
01.08.2009
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 8/2009
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-009-1648-6

Weitere Artikel der Ausgabe 8/2009

Die Onkologie 8/2009 Zur Ausgabe

In der Diskussion: Komplementäre Onkologie

Ayurveda

Neu im Fachgebiet Onkologie

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.